These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 25223952)

  • 1. Aripiprazole augmentation of antidepressants for postpartum depression: a preliminary report.
    Sharma V; Sommerdyk C; Xie B
    Arch Womens Ment Health; 2015 Feb; 18(1):131-4. PubMed ID: 25223952
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effectiveness and safety of adjunctive aripiprazole in Taiwanese patients with antidepressant-refractory major depressive disorder: a prospective, open-label trial.
    Chen SJ; Hsiao YL; Shen TW; Chen ST
    J Clin Psychopharmacol; 2012 Feb; 32(1):56-60. PubMed ID: 22198444
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Aripiprazole augmentation of antidepressants for the treatment of partially responding and nonresponding patients with major depressive disorder.
    Simon JS; Nemeroff CB
    J Clin Psychiatry; 2005 Oct; 66(10):1216-20. PubMed ID: 16259533
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Aripiprazole augmentation in major depressive disorder: a double-blind, placebo-controlled study in patients with inadequate response to antidepressants.
    Berman RM; Fava M; Thase ME; Trivedi MH; Swanink R; McQuade RD; Carson WH; Adson D; Taylor L; Hazel J; Marcus RN
    CNS Spectr; 2009 Apr; 14(4):197-206. PubMed ID: 19407731
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Aripiprazole augmentation for major depressive disorder: dosing patterns in a naturalistic treatment setting.
    Pae CU; Wang SM; Han C; Lee SJ; Patkar AA; Masand PS
    Int Clin Psychopharmacol; 2014 Mar; 29(2):116-9. PubMed ID: 24108149
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Augmentation of aripiprazole for depressed patients with an inadequate response to antidepressant treatment: a 6-week prospective, open-label, multicenter study.
    Jon DI; Kim DH; Seo HJ; Kwon YJ; Kim MD; Yang JC; Suh HS; Min KJ; Pae CU; Bahk WM
    Clin Neuropharmacol; 2013; 36(5):157-61. PubMed ID: 24045606
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aripiprazole augmentation, antidepressant combination or switching therapy in patients with major depressive disorder who are partial- or non-responsive to current antidepressants: a multi-center, naturalistic study.
    Han C; Wang SM; Seo HJ; Lee BC; Jeon HJ; Kim W; Kwak KP; Pae CU
    J Psychiatr Res; 2014 Feb; 49():75-82. PubMed ID: 24268719
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adjunctive aripiprazole in major depressive disorder: analysis of efficacy and safety in patients with anxious and atypical features.
    Trivedi MH; Thase ME; Fava M; Nelson CJ; Yang H; Qi Y; Tran QV; Pikalov A; Carlson BX; Marcus RN; Berman RM
    J Clin Psychiatry; 2008 Dec; 69(12):1928-36. PubMed ID: 19192475
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adjunctive low-dose aripiprazole with standard-dose sertraline in treating fresh major depressive disorder: a randomized, double-blind, controlled study.
    Lin CH; Lin SH; Jang FL
    J Clin Psychopharmacol; 2011 Oct; 31(5):563-8. PubMed ID: 21869699
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Aripiprazole adjunctive to antidepressant therapy.
    Marcus RM; Sanchez R; Frost M; McQuade RD
    Am J Psychiatry; 2011 Feb; 168(2):211; author reply 211. PubMed ID: 21297051
    [No Abstract]   [Full Text] [Related]  

  • 11. Analysis of suicidality in pooled data from 2 double-blind, placebo-controlled aripiprazole adjunctive therapy trials in major depressive disorder.
    Weisler RH; Khan A; Trivedi MH; Yang H; Eudicone JM; Pikalov A; Tran QV; Berman RM; Carlson BX
    J Clin Psychiatry; 2011 Apr; 72(4):548-55. PubMed ID: 20816039
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a second multicenter, randomized, double-blind, placebo-controlled study.
    Marcus RN; McQuade RD; Carson WH; Hennicken D; Fava M; Simon JS; Trivedi MH; Thase ME; Berman RM
    J Clin Psychopharmacol; 2008 Apr; 28(2):156-65. PubMed ID: 18344725
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aripiprazole in refractory depression?
    Carroll BJ
    J Clin Psychopharmacol; 2009 Feb; 29(1):90-1; author reply 92-3. PubMed ID: 19142117
    [No Abstract]   [Full Text] [Related]  

  • 14. Effectiveness of aripiprazole, olanzapine, quetiapine, and risperidone augmentation treatment for major depressive disorder: a nationwide population-based study.
    Lin CY; Tsai GE; Wang HS; Wu YH; Chiou CC; Wu VY; Lane HY
    J Clin Psychiatry; 2014 Sep; 75(9):e924-31. PubMed ID: 25295435
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aripiprazole augmentation of tranylcypromine in treatment-resistant major depression.
    Goforth HW; Carroll BT
    J Clin Psychopharmacol; 2007 Apr; 27(2):216-7. PubMed ID: 17414252
    [No Abstract]   [Full Text] [Related]  

  • 16. Global benefit-risk analysis of adjunctive aripiprazole in the treatment of patients with major depressive disorder.
    Wisniewski SR; Chen CC; Kim E; Kan HJ; Guo Z; Carlson BX; Tran QV; Pikalov A
    Pharmacoepidemiol Drug Saf; 2009 Oct; 18(10):965-72. PubMed ID: 19662630
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Aripiprazole augmentation of selective serotonin reuptake inhibitors for treatment-resistant major depressive disorder.
    Papakostas GI; Petersen TJ; Kinrys G; Burns AM; Worthington JJ; Alpert JE; Fava M; Nierenberg AA
    J Clin Psychiatry; 2005 Oct; 66(10):1326-30. PubMed ID: 16259548
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of the efficacy between paroxetine and sertraline augmented with aripiprazole in patients with refractory major depressive disorder.
    Yoshimura R; Kishi T; Hori H; Ikenouchi-Sugita A; Katsuki A; Umene-Nakano W; Iwata N; Nakamura J
    Prog Neuropsychopharmacol Biol Psychiatry; 2012 Dec; 39(2):355-7. PubMed ID: 22813840
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A prospective, open-label study of Aripiprazole mono- and adjunctive treatment in acute bipolar depression.
    Dunn RT; Stan VA; Chriki LS; Filkowski MM; Ghaemi SN
    J Affect Disord; 2008 Sep; 110(1-2):70-4. PubMed ID: 18272230
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Response and remission rates with adjunctive aripiprazole in patients with major depressive disorder who exhibit minimal or no improvement on antidepressant monotherapy.
    Casey DE; Laubmeier KK; Eudicone JM; Marcus R; Berman RM; Rahman Z; Sheehan J
    Int J Clin Pract; 2014 Nov; 68(11):1301-8. PubMed ID: 25196314
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.